Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (467)	4/7/2004 10:14:22 AM
From: nigel bates	Respond to of 625

Dunno....someone realised that CAT was valued at less than DYAX ?

To: Madharry who wrote (467)	4/8/2004 7:54:12 AM
From: nigel bates	Respond to of 625

Abbott Reports 13.9 Percent Sales Increase in the First Quarter Thursday April 8, 7:15 am ET - Company Provides 2005 HUMIRA(R) Sales Forecast of More Than $1.2 Billion Based on Strong Global Demand; Hospira Spin-Off on Track for Second Quarter - ABBOTT PARK, Ill., April 8 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT - News) today announced financial results for the first quarter ended March 31, 2004. * Worldwide sales for the quarter were $5.216 billion, up 13.9 percent from $4.580 billion in the first quarter of 2003. Total sales were favorably impacted 4.9 percent due to the effect of exchange rates. * Abbott's diluted earnings per share increased 11.8 percent to $0.57, excluding previously announced one-time charges related to acquisitions and the planned spin-off of Hospira - within the company's previous guidance of $0.55 to $0.57. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) increased 2.0 percent to $0.52. * U.S. pharmaceutical sales grew 24.4 percent, driven by strong growth across virtually all branded products, including Depakote(R), Synthroid(R), TriCor(R), Omnicef(R) and Ultane(R). * Worldwide HUMIRA(R) sales were $149 million, including $47 million in international sales, exceeding company forecasts. As a result, Abbott for the first time is providing worldwide sales guidance of more than $1.2 billion for 2005.....